Gao Dongyu, Zheng Xu, Luo Jiawen, Li Shuhe, Hu Jiahao, Gao Xue, Zhan Tiexiang, Sun Ziyi, Chou Shuli, Zeng Xianguo, Jiang Qingru, Luo Liang
Intensive Care Unit, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong Province, China.
University of Exeter Medical School, University of Exeter, Heavitree Road, Exeter, EX12LU, UK.
BMC Microbiol. 2025 Aug 8;25(1):489. doi: 10.1186/s12866-025-04160-8.
Fungal infections often co-occur with antibiotic-resistant bacterial infections, posing clinical treatment challenges. Antimicrobial peptides (AMPs) are considered promising therapeutic alternatives due to their low potential for inducing drug resistance. This study aimed to enhance the antibacterial potency of an existing antifungal peptide through optimization, developing a dual-function peptide targeting both fungal and bacterial pathogens.
We designed peptides F1-F4 from the symmetrical amino acid-paired antifungal peptide P19 through threonine (T) substitution and hydrophobic moment (µHrel) adjustment. Then, we assessed their antifungal and antibacterial activities against reference and clinically isolated strains by minimum inhibitory concentrations (MICs), evaluated their toxicity to human red blood cells, and explored the membrane-associated mechanisms.
Peptide F4 was the most promising candidate due to its potent antifungal and antibacterial activities, lack of inhibitory effect on beneficial lactobacilli at concentrations effective against pathogens, and low hemolytic activity. F4 also exhibited strong binding affinity to lipopolysaccharides (LPS) and induced bacterial membrane depolarization and permeabilization.
Our findings demonstrated that T substitution and hydrophobic moment adjustment effectively enhanced antibacterial activity of the antifungal peptide P19, making peptide F4 a strong candidate for both fungal and bacterial infections.
真菌感染常与耐抗生素细菌感染同时发生,给临床治疗带来挑战。抗菌肽(AMPs)因其诱导耐药性的可能性低而被认为是有前景的治疗替代方案。本研究旨在通过优化提高现有抗真菌肽的抗菌效力,开发一种针对真菌和细菌病原体的双功能肽。
我们通过苏氨酸(T)取代和疏水矩(µHrel)调整,从对称氨基酸配对的抗真菌肽P19设计了肽F1 - F4。然后,我们通过最低抑菌浓度(MICs)评估它们对参考菌株和临床分离菌株的抗真菌和抗菌活性,评估它们对人红细胞的毒性,并探索膜相关机制。
肽F4是最有前景的候选物,因为它具有强大的抗真菌和抗菌活性,在对病原体有效的浓度下对有益乳酸杆菌没有抑制作用,并且溶血活性低。F4还表现出与脂多糖(LPS)的强结合亲和力,并诱导细菌膜去极化和通透性增加。
我们的研究结果表明,T取代和疏水矩调整有效地增强了抗真菌肽P19的抗菌活性,使肽F4成为治疗真菌和细菌感染的有力候选物。